Visum Therapeutics
-
2010
Company Description
Develops small molecule y p p g therapeutic to treat Stargardt's disease,
Visum Therapeutics develops small molecule y p p g therapeutic to treat Stargardt's disease, a degenerative condition that leads to blindness and is the most common form of inherited juvenile macular degeneration. Much of the pathology of Stargardt's disease is shared with the more common Age-related Macular Degeneration (AMD).
-
Manufacturer:
Science and Engineering -
Formed:
2010 -
Company Website:
-
Company E-mail:
-
Company Address:
Cleveland, OHUnited States -
CEO:
- William Harte
-
We recognize our sponsors starting at $1 per entry.
Learn more at https://www.ithistory.org/benefits